Novel antibiotics: Are we still in the pre–post-antibiotic era?

44Citations
Citations of this article
98Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed. Methods: This paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials. Conclusion: Each of these new trials increases the possibility of new antibiotics receiving approval.

Cite

CITATION STYLE

APA

Draenert, R., Seybold, U., Grützner, E., & Bogner, J. R. (2015, April 1). Novel antibiotics: Are we still in the pre–post-antibiotic era? Infection. Urban und Vogel GmbH. https://doi.org/10.1007/s15010-015-0749-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free